UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis

Science signaling, 2009-06, Vol.2 (77), p.ra31

2009

Volltextzugriff (PDF)

Interaction of the Response Regulator ARR4 with Phytochrome B in Modulating Red Light Signaling

Science (American Association for the Advancement of Science), 2001-11, Vol.294 (5544), p.1108-1111

2001

Volltextzugriff (PDF)

Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients

The American journal of pathology, 2013-11, Vol.183 (5), p.1446-1460

2013

Volltextzugriff (PDF)

Differentially Expressed Fibroblast Growth Factors Regulate Skeletal Muscle Development through Autocrine and Paracrine Mechanisms

The Journal of cell biology, 1996-03, Vol.132 (6), p.1151-1159

1996

Volltextzugriff (PDF)

Ca2+ signaling in plant responses to abiotic stresses

Journal of integrative plant biology, 2022-02, Vol.64 (2), p.287-300

2022

Volltextzugriff (PDF)

Genes for calcineurin B-like proteins in Arabidopsis are differentially regulated by stress signals

Proceedings of the National Academy of Sciences - PNAS, 1999-04, Vol.96 (8), p.4718-4723

1999

Volltextzugriff (PDF)

Molecular characterization of a FKBP-type immunophilin from higher plants

Proceedings of the National Academy of Sciences - PNAS, 1996-07, Vol.93 (14), p.6964-6969

1996

Volltextzugriff (PDF)

The FGF Receptor-1 Tyrosine Kinase Domain Regulates Myogenesis but Is Not Sufficient to Stimulate Proliferation

The Journal of cell biology, 1998-07, Vol.142 (1), p.241-250

1998

Volltextzugriff (PDF)

Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab

Clinical cancer research, 2017-01, Vol.23 (1_Supplement), p.A19-A19

2017

Volltextzugriff (PDF)

Conservation of Ligand Specificity between the Mammalian and Amphibian Fibroblast Growth Factor Receptors

The Journal of biological chemistry, 1995-12, Vol.270 (48), p.29018-29024

1995

Volltextzugriff (PDF)

Potential regulators of HER2 activity in HER2-overexpressing gastric and gastroesophageal tumors: Analysis of HER3 and heregulin expression

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.48-48

2014

Volltextzugriff (PDF)

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS9110-TPS9110

2016

Volltextzugriff (PDF)

Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4043-4043

2016

Volltextzugriff (PDF)

Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.48-48

2013

Volltextzugriff (PDF)

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-06-01-OT3-06-01

2018

Volltextzugriff (PDF)

The Effects of Strategic Planning on Common Stock Returns

Academy of Management journal, 1980-03, Vol.23 (1), p.5-20

Kudla, Ronald J.

1980

Volltextzugriff (PDF)

Abstract 1888: MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growth

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1888-1888

2012

Volltextzugriff (PDF)

Abstract P6-15-02: Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-15-02

2017

Volltextzugriff (PDF)

Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS4148-TPS4148

2014

Volltextzugriff (PDF)

Abstract 655: Combination of MM-111, an ErbB2/ErbB3 bispecific antibody, with endocrine therapies as an effective strategy for treatment of ER+/HER2+ breast cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.655-655

2011

Volltextzugriff (PDF)

Abstract 654: MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.654-654

2011

Volltextzugriff (PDF)

Abstract 3485: MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3485-3485

2010

Volltextzugriff (PDF)

Heteromeric AtKC1Â·AKT1 Channels in Arabidopsis Roots Facilitate Growth under K+-limiting Conditions

The Journal of biological chemistry, 2009-08, Vol.284 (32), p.21288

2009

Volltextzugriff (PDF)

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

Clinical cancer research, 2019-08, Vol.25 (16), p.5107-5121

2019

Volltextzugriff (PDF)

The Microeconomic Consequences of an Involuntary Corporate Spin-off

MIT Sloan management review, 1981-07, Vol.22 (4), p.41

1981

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Aktive Filter

KollektionNUS Single-Journal Subscriptions

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(43)

Publikationsform

Artikel
(50)
Tagungsberichte
(2)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis

Interaction of the Response Regulator ARR4 with Phytochrome B in Modulating Red Light Signaling

Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients

Differentially Expressed Fibroblast Growth Factors Regulate Skeletal Muscle Development through Autocrine and Paracrine Mechanisms

Ca2+ signaling in plant responses to abiotic stresses

Genes for calcineurin B-like proteins in Arabidopsis are differentially regulated by stress signals

Molecular characterization of a FKBP-type immunophilin from higher plants

The FGF Receptor-1 Tyrosine Kinase Domain Regulates Myogenesis but Is Not Sufficient to Stimulate Proliferation

Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab

Conservation of Ligand Specificity between the Mammalian and Amphibian Fibroblast Growth Factor Receptors

Potential regulators of HER2 activity in HER2-overexpressing gastric and gastroesophageal tumors: Analysis of HER3 and heregulin expression

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)

Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC)

Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

The Effects of Strategic Planning on Common Stock Returns

Abstract 1888: MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growth

Abstract P6-15-02: Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models

Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy

Abstract 655: Combination of MM-111, an ErbB2/ErbB3 bispecific antibody, with endocrine therapies as an effective strategy for treatment of ER+/HER2+ breast cancer

Abstract 654: MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells

Abstract 3485: MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit

Heteromeric AtKC1Â·AKT1 Channels in Arabidopsis Roots Facilitate Growth under K+-limiting Conditions

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

The Microeconomic Consequences of an Involuntary Corporate Spin-off

Aktive Filter

Suchergebnisse filtern